Small molecule high throughput screen using AstraZeneca facilities (Grant)
UK Research and Innovation, Medical Research Council is offering a funding call in United Kingdom. Applications close on 8 Sept 2027. What it covers is set out below in the issuer's own words.
At a glance
- Type
- Funding
- Offered by
- UK Research and Innovation, Medical Research Council (Public funding)
- Where
- United Kingdom
- Value
- Up to £270,000
- Who can apply
- Public Sector, Non-profit, Private Sector
- Closes
- 8 Sept 2027
- How to apply
- On the issuer's own website
In the issuer's words
Apply for funding to run a high throughput screen (HTS) using AstraZeneca’s compound library and screening robots.
There are two funding opportunities per year that are open to all targets.
Apply for funding to run a high throughput screen (HTS) using AstraZeneca’s compound library and screening robots.
There are two funding opportunities per year, that are open to all targets.
This opportunity is open to organisations with standard eligibility. Check if your organisation is eligible .
To be eligible to apply for this funding opportunity you must show that you will direct the project and be actively engaged in the work.
For applicants who do not have a contract of employment for the duration of the proposed project, by submitting an application the research organisation is confirming, if it is successful:
contracts will be extended beyond the end date of the project
all necessary support for the project and the applicants will be provided, including mentorship and career development for early career researchers
You can only submit one application as project lead to this funding opportunity.
We will not accept uninvited resubmission of applications that were submitted after 1 April 2026 to Medical Research Council (MRC), the rest of UK Research and Innovation (UKRI) or any other funder. An uninvited resubmission is an application that was previously unsuccessful and has been submitted again without being invited by MRC. This includes applications that are unchanged, minimally revised, or substantially the same as the original submission. Uninvited resubmissions will be rejected.
You should contact us if you are unsure whether your application is a resubmission. Find contacts in the ‘contact details’ section.
Research applications that are led by commercial entities are not eligible. Applications may not include collaborations with additional commercial parties.
You are also not eligible to apply for this funding opportunity as a project lead if you are based at an international research organisation. This does not include MRC Unit The Gambia or MRC/UVRI Uganda Research Unit at the London School of Hygiene and Tropical Medicine that are eligible to apply as project lead.
We are committed to achieving equality of opportunity for all funding applicants. We encourage applications from a diverse range of researchers.
We support people to work in a way that suits their personal circumstances. This includes:
support for people with caring responsibilities
UKRI can offer disability and accessibility support for UKRI applicants and grant holders during the application and assessment process.
Demand management is being applied to this funding opportunity. Further details are provided in the ‘who can apply’ section.
The small molecule HTS using AstraZeneca facilities funding opportunity aims to support academic researchers in discovering potential starting points for small molecule medicinal drugs.
Academic researchers will benefit from unprecedented access to over two million molecules in AstraZeneca’s compound library, as well as its state-of-the-art high-throughput screening facilities.
Medical Research Council (MRC) will provide funding to support up to four projects per year. As capacity is limited, projects will be prioritised for funding and for time slots within the facility. The timeframe for commencement of the studies will vary, although the expectation is within six months of the funding decision.
AstraZeneca may offer to fund a project in its entirety if, based on the application, it considers that route to be the most appropriate funding mechanism for that individual study. In such cases, these will be taken forward through direct collaboration with the company without any further MRC involvement. Applicants who do not wish to accept this offer may continue to seek MRC support through the initiative.
AstraZeneca will provide technical input to support assay optimisation, investigation of alternative readout technologies and pilot HTS screen, prior to transfer of the assay to the HTS platform. Depending on the results of the optimisation, a compound set of between 100,000 and 1 million of the library will be screened.
There are a number of minimum assay development guidelines which when considered as a whole will need to provide evidence that a screen could be conducted. Funds are provided to complete the assay development, so a less well-developed assay is not a barrier to your application being competitive.
The duration of this award is typically 15 months. However, the duration can be from 12 (minimum) to a maximum of 18 months.
he full economic cost (FEC) of your project can be up to £270,000 (£250,000 cost to MRC).
We will fund 100% FEC of the work conducted at AstraZeneca.
We will fund 80% FEC of any work conducted at the research organisation or related to staff costs, subsistence and travel.
We will fund costs related to staff and consumables incurred at AstraZeneca for the optimisation and execution of the HTS. These include:
£20,000 (100% FEC exceptions) for optimisation and establishment of an HTS
£150,000 (100% FEC exceptions) for execution of the HTS
cost of travel, accommodation and subsistence for a host institution researcher to work at AstraZeneca in Cambridge for three months (80% FEC)
costs for elements of the screening cascade that cannot be undertaken at AstraZeneca and must be undertaken at the host organisation (80% FEC)
minimal percentage of full-time equivalent for the project lead (80% FEC)
This funding opportunity highly encourages a researcher from the host institution to embed themselves at the AstraZeneca facilities in Cambridge for a period of up to three months total. This will help with the establishment of the assay and conducting the HTS.
More from UK Research and Innovation, Medical Research Council
- Efficient, Structured and Controllable AI Systems Innovate UK, part of UK Research and Innovation (UKRI)
- Trees, woodlands and forestry - Woodland Creation Planning Grant Department for Environment Food and Rural Affairs / Forestry Commission – Defra Trees Programme
- Community and Environment Fund (CEF) and Business and Local Economy Fund (BLEF) HS2 Ltd
- England Woodland Creation Offer (EWCO) Department for Environment, Food and Rural Affairs / Forestry Commission – Defra Trees Programme
- International Travel Award Scheme for the Biological Sciences (Grant) UK Research and Innovation, Biotechnology and Biological Sciences Research Council
- Electric Vehicle Chargepoint Grant for Renters and Flat Owners Office for Zero Emission Vehicles
Similar offers in United Kingdom
- Wellcome Early-Career Awards Wellcome
- Wellcome Career Development Awards Wellcome
- Wellcome Discovery Awards Wellcome
- Springboard Awards Wellcome
- Starter Grants for Clinical Lecturers Wellcome
- PhD Fellowships for Health Professionals Wellcome